TW275632B - - Google Patents

Info

Publication number
TW275632B
TW275632B TW081103168A TW81103168A TW275632B TW 275632 B TW275632 B TW 275632B TW 081103168 A TW081103168 A TW 081103168A TW 81103168 A TW81103168 A TW 81103168A TW 275632 B TW275632 B TW 275632B
Authority
TW
Taiwan
Prior art keywords
mutant rsv
rsv
pharmaceutical compositions
mutant
vaccinating
Prior art date
Application number
TW081103168A
Other languages
English (en)
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of TW275632B publication Critical patent/TW275632B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18564—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW081103168A 1992-04-21 1992-04-22 TW275632B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87142092A 1992-04-21 1992-04-21

Publications (1)

Publication Number Publication Date
TW275632B true TW275632B (zh) 1996-05-11

Family

ID=25357402

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081103168A TW275632B (zh) 1992-04-21 1992-04-22

Country Status (13)

Country Link
US (1) US5932222A (zh)
EP (1) EP0567100B1 (zh)
JP (1) JPH0622756A (zh)
AT (1) ATE177785T1 (zh)
AU (1) AU671983B2 (zh)
CA (1) CA2094464C (zh)
DE (1) DE69323921T2 (zh)
DK (1) DK0567100T3 (zh)
ES (1) ES2130189T3 (zh)
GR (1) GR3029716T3 (zh)
NZ (1) NZ247444A (zh)
TW (1) TW275632B (zh)
ZA (1) ZA932763B (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2257744T3 (es) * 1994-10-05 2006-08-01 Vanderbilt University Interleuquina-12 como adyuvante para vacunas contra paramyxoviridae.
US6689367B1 (en) * 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US7846455B2 (en) * 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
US6015664A (en) * 1995-11-03 2000-01-18 Mcw Research Foundation Multiplex PCR assay using unequal primer concentrations to detect HPIV 1,2,3 and RSV A,B and influenza virus A, B
US6077514A (en) * 1996-04-04 2000-06-20 The Regents Of The University Of Michigan Attenuated respiratory syncytial virus
AU2438597A (en) * 1996-04-04 1997-10-29 Regents Of The University Of Michigan, The Attenuated respiratory syncytial virus
AU4427897A (en) * 1996-09-27 1998-04-17 American Cyanamid Company 3' genomic promoter region and polymerase gene mutations responsible for att enuation in viruses of the order designated mononegavirales
DE19729161A1 (de) 1997-07-08 1999-01-14 Basf Ag Thermisch härtbare, wässrige Zusammensetzungen
CN1273603A (zh) * 1997-09-19 2000-11-15 美国氰胺公司 减毒的呼吸道合胞病毒
EP1064358A2 (en) * 1998-03-26 2001-01-03 American Cyanamid Company Mutations responsible for attenuation in measles virus or human respiratory syncytial virus subgroup b
US20040052800A1 (en) * 2000-08-07 2004-03-18 Bruce Carpick Stabilization of immunogens derived from paramyxoviruses
WO2005058356A2 (en) * 2003-12-17 2005-06-30 Wyeth Methods for porducing storage stable viruses and immunogenic compositions thereof
GB201202091D0 (en) 2012-02-07 2012-03-21 Renishaw Ireland Ltd Drug delivery apparatus
GB201202093D0 (en) * 2012-02-07 2012-03-21 Renishaw Ireland Ltd Drug storage apparatus
CN112501134B (zh) * 2020-12-09 2023-01-20 贵州医科大学附属医院 一种人呼吸道合胞病毒毒株及其应用
CN113462656B (zh) * 2021-03-24 2022-09-30 兰州生物制品研究所有限责任公司 一种人三型副流感病毒冷适应温度敏感株及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149650A (en) * 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
JPH01501357A (ja) * 1986-01-14 1989-05-18 ユニバ−シテイ・オブ・ノ−ス・カロライナ ヒト呼吸器系ウイルス用ワクチン
US5223254A (en) * 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
AU2715288A (en) * 1987-11-20 1989-06-14 Upjohn Company, The Human respiratory syncytialvirus vaccine derived from the 1a (9.5 kd) protein
JP2716503B2 (ja) * 1987-12-23 1998-02-18 ジ・アップジョン・カンパニー ヒト呼吸系シンシチウムウイルスの糖蛋白類の免疫原性セグメントを含有するキメラ糖蛋白類
IL105456A (en) * 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus

Also Published As

Publication number Publication date
ATE177785T1 (de) 1999-04-15
US5932222A (en) 1999-08-03
CA2094464C (en) 2005-08-23
AU671983B2 (en) 1996-09-19
ZA932763B (en) 1994-02-08
AU3705793A (en) 1993-10-28
GR3029716T3 (en) 1999-06-30
CA2094464A1 (en) 1993-10-22
NZ247444A (en) 1994-12-22
ES2130189T3 (es) 1999-07-01
JPH0622756A (ja) 1994-02-01
EP0567100A1 (en) 1993-10-27
DE69323921D1 (de) 1999-04-22
DE69323921T2 (de) 1999-08-26
EP0567100B1 (en) 1999-03-17
DK0567100T3 (da) 1999-09-27

Similar Documents

Publication Publication Date Title
TW275632B (zh)
EP1712628A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO1998016646A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO1998053075A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
WO1999042076A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
HK1043943A1 (zh) 肺炎鏈球菌蛋白質和疫苗
CA2022420A1 (en) Escherichia coli vaccine
HUT69796A (en) Vaccine against streptococcus suis infection
PL301576A1 (en) Novel hiv protease inhibitors, method of obtaining such inhibitors, pharmaceutical preparation and novel initial compounds
EP1891968A3 (en) Rotavirus vaccine formulations
MX9708426A (es) Polipeptido hk2 de variante estable.
WO1992006113A3 (en) Derivatives of gp160 and vaccines based on gp160 or a derivative thereof, containing an adjuvant
AU653861B2 (en) Respiratory disease vaccine for cats
DK284588A (da) Beta-lactam-forbindelser, deres fremstilling og anvendelse som laegemidler.
DK0626173T3 (da) Aerosolpræparat indeholdende fusafungin
UA42741C2 (uk) Пептид маститної вакцини (варіанти), пептид складного антигенного представлення (варіанти), фармацевтична композиція (варіанти)
AU8177494A (en) Process for preparing clear sera which are stable over a long period
CY1108864T1 (el) Ενωσεις για ανοσοθεραπεια και διαγνωση φυματιωσης και μεθοδοι χρησεις τους